| 英文摘要 |
Type 2 diabetes mellitus (T2DM) is a chronic, progressive and incurable disease associated with ever-increasing morbidity and mortality resulting in considerable socioeconomic burden for healthcare systems worldwide. In the past, many T2DM patients failing oral therapy had to rely on insulin injection eventually. Fortunately, in recent years, there have been several breakthroughs in the development of oral antidiatetic drugs (OADs) that help delay the reliance; the latest one available in the market is the sodium-glucose cotransporter 2 inhibitors (SGLT2i), whose mechanism of action is independent of insulin. The article shows how a case with OADs failure was successfully treated by replacing the original dipeptidyl peptidase-4 inhibitors (DPP4i) with SGLT2i in combination with metformin. The SGLT2i further helped reduce the types of OADs and the overall drug expenses. For patients failing oral therapy, the insulin-independent SGLT2i may be an effective alternative. Recently, however, the U.S. Food and Drug Administration (FDA) has issued warnings about the side effects of the drug. The FDA reports and related studies had accordingly been reviewed and the indications, side effects, contraindications and extra-benefit of SGLT2i listed in a comprehensive manner to provide medical professionals with appropriate reference. |
